Systemic Aspergillosis and Systemic Candidiasis Market Report 2025

The systemic aspergillosis and systemic candidiasis market size has grown steadily in recent years. It will grow from $7.24 billion in 2024 to $7.59 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of fungal infections, immunocompromised patient population, improved diagnostic technologies, rise in invasive medical procedures, global spread of infections.

The systemic aspergillosis and systemic candidiasis market size is expected to see strong growth in the next few years. It will grow to $9.28 billion in 2029 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to global antifungal resistance surveillance, aging population, telemedicine for remote consultations, patient-centric drug development, digital health solutions for patient management. Major trends in the forecast period include new fungal biomarkers for early detection, the emergence of novel antifungal agents, advancements in immunotherapy, and innovative drug delivery systems.

The rising incidence of fungal diseases is projected to drive the growth of the systemic aspergillosis and systemic candidiasis market in the future. Fungal diseases are infections caused by fungi that can impact various parts of the body, leading to a range of symptoms and complications. These infections can manifest as cutaneous skin infections, respiratory issues, and systemic conditions. Treatment typically involves antifungal medications, including oral azoles, voriconazole, and liposomal amphotericin B. For example, in July 2024, *The Lancet*, a respected medical journal based in London, reported estimates indicating there are 6.5 million cases of invasive fungal infections each year, resulting in 3.8 million deaths, with approximately 2.5 million of these fatalities directly attributed to the infections. Consequently, the rising incidence of fungal diseases is fueling the growth of the systemic aspergillosis and systemic candidiasis market.

The escalation in healthcare expenditures is anticipated to stimulate the growth of the systemic aspergillosis and systemic candidiasis market in the future. Healthcare expenditures refer to the total amount of money allocated for medical services, treatments, and health-related expenses over a specific period. Increased healthcare spending can facilitate the management of systemic aspergillosis and systemic candidiasis by providing timely access to antifungal medications, advanced diagnostic tools, and specialized care, thus improving patient outcomes and lowering mortality rates. For instance, in May 2023, a report from the Office for National Statistics, a UK government department, revealed that healthcare spending in the UK rose by 5.6% between 2022 and 2023, compared to a growth of 0.9% in 2022. The UK's healthcare expenditure was approximately $317.63 billion (£292 billion) in 2023. Therefore, the increase in healthcare spending is contributing to the growth of the systemic aspergillosis and systemic candidiasis market.

Leading companies in the systemic aspergillosis and systemic candidiasis markets are focusing on developing advanced products like echinocandins to improve treatment efficacy and tackle the increasing challenges posed by antifungal resistance. Echinocandins represent a class of antifungal medications that inhibit the synthesis of β-glucan, a vital component of the fungal cell wall. For example, in March 2023, Cidara Therapeutics and Melinta Therapeutics, both US-based biotechnology firms, received approval from the Food and Drug Administration (FDA), the federal agency responsible for public health protection in the US, for REZZAYO (rezafungin for injection). REZZAYO is an innovative once-weekly echinocandin aimed at treating candidemia in adults who have limited or no alternative treatment options. Its once-weekly dosing regimen is designed for ease of administration, streamlining treatment and improving continuity of care for patients with invasive candidiasis, especially those in hospital environments where effective infection management is essential.

Major companies in the systemic aspergillosis and systemic candidiasis market are also focusing on advanced solutions, such as next-generation anti-fungal drug agents, to address the growing demand for more effective and targeted treatments. Next-generation anti-fungal drug agents involve advanced medications designed to combat fungal infections more effectively, often incorporating innovative mechanisms or formulations to enhance efficacy and reduce resistance. For example, in October 2023, BDR Pharmaceutical, a US-based pharmaceutical company, launched Zisavel capsules for treating invasive aspergillosis and mucormycosis. This product, belonging to the isavuconazoles class of medications, plays a crucial role in treating invasive aspergillosis and offers a first-line treatment for the specified fungal infections.

In August 2023, Sandoz, a global pharmaceutical company based in Germany, acquired Astellas Pharma Inc. for an undisclosed sum. This acquisition is intended to significantly enhance Sandoz's hospital offerings and broaden its anti-infectives portfolio, allowing the company to deliver essential antimicrobial medicines and promote responsible use through targeted therapies for patients in need. Astellas Pharma Inc., a global pharmaceutical company based in Japan, specializes in treatments for systemic aspergillosis and systemic candidiasis.

Major companies operating in the systemic aspergillosis and systemic candidiasis market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC.

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the systemic aspergillosis and systemic candidiasis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Systemic aspergillosis, the most lethal form of aspergillosis, occurs when the infection extends beyond the lungs to affect other organs. On the other hand, systemic candidiasis encompasses a range of yeast infections caused by various Candida species. Both conditions are serious illnesses capable of damaging organs such as the blood, heart, brain, eyes, bones, and others.

The primary types of treatments for systemic aspergillosis and systemic candidiasis include systemic oral azoles, voriconazole, liposomal amphotericin B, topical antifungal agents, and others. Systemic oral azoles constitute a class of antifungal medications taken orally to combat systemic fungal infections throughout the body. These drugs target specific enzymes crucial for fungal survival, thereby inhibiting the growth and replication of fungal cells. They find application in treating conditions such as allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), gastrointestinal candidiasis, genitourinary tract candidiasis, and others. The usage is prevalent in clinics, hospitals, and other healthcare settings.

The systemic aspergillosis and systemic candidiasis research report is one of a series of new reports that provides systemic aspergillosis and systemic candidiasis market statistics, including the systemic aspergillosis and systemic candidiasis industry's global market size, regional shares, competitors with systemic aspergillosis and systemic candidiasis market share, detailed systemic aspergillosis and systemic candidiasis market segments, market trends and opportunities, and any further data you may need to thrive in the systemic aspergillosis and systemic candidiasis industry. This systemic aspergillosis and systemic candidiasis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The systemic aspergillosis and systemic candidiasis market consists of sales of voriconazole and amphotericin B. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.